Development of the CK‐MB‐1 trastuzumab‐resistant HER2‐positive breast cancer cell line and xenograft animal models

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer who fail to respond to anti‐HER2 treatments have poor prognoses. Most trastuzumab‐resistant breast cancer cell lines available from biobanks feature either phosphoinositide‐3‐kinase, catalytic, alpha (PI...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Wei‐Pang, Huang, Wei‐Lun, Liao, Wei‐An, Huang, Wan‐Ling, Liu, You‐Yu, Su, Wu‐Chou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982635/
https://www.ncbi.nlm.nih.gov/pubmed/33665980
http://dx.doi.org/10.1002/cam4.3824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982635/
https://www.ncbi.nlm.nih.gov/pubmed/33665980
http://dx.doi.org/10.1002/cam4.3824

Ejemplares similares